Abstract: The present application relates to methods to administer to a patient a hypothermal inhalation gas composition that includes oxygen and a mixture of inert gases. The mixture of inert gases includes a first compound selected from xenon and argon, and a second compound having hypothermal properties, such as helium. In the methods, a gas composition including oxygen and a mixture of inert gases is selected and the gas composition is administered to the patient at an inhalation temperature of a specified range such that the body temperature of the patient is maintained within a specified temperature range.
Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Abstract: A method of inhibiting migration of a cancer cell of a tumor in a subject comprising the steps of: (a) contacting the tumor with a gold nanomaterial; and (b) irradiating the tumor with an irradiation source.
Type:
Grant
Filed:
July 6, 2018
Date of Patent:
June 29, 2021
Assignee:
Georgia Tech Research Corporation
Inventors:
Mostafa A. El-Sayed, Moustafa R. K. Ali
Abstract: Described herein are compositions that include a saline solution and reactive oxygen species. Specifically, the composition may include a saline solution, reactive oxygen species, an emollient, and a pH modifier. Also provided is a gel composition that includes a rheology agent. Also provided are methods of making and using the compositions.
Abstract: The tablet of the present invention is a tablet 1 having a cup portion 12 formed at least above or below a side portion 11, wherein the outer surface of the cup portion 12 includes first, second and third curved surfaces 12a, 12b and 12c having different curvatures R1, R2 and R3, the first curved surface 12a is at least continuous with the second curved surface 12b, the second curved surface 12b is continuous with the first curved surface 12a and the third curved surface 12c, and the third curved surface 12c is at least continuous with the second curved surface 12b.
Abstract: Disclosed herein are nanoparticle compositions and methods of use such as for chemoprevention of cancer, for example oral squamous cell carcinoma (OSCC). The nanoparticle composition comprises a Janus particle comprising at least two chemopreventive agents, wherein at least one of the chemopreventive agents is selected from freeze-dried black raspberries (BRB), a synthetic vitamin A analogue, N-acetylcysteine (NAC), and an anti-interleukin 6 agent. Methods for improving oral health comprising administering to a subject the nanoparticle compositions are also disclosed.
Type:
Grant
Filed:
March 16, 2018
Date of Patent:
June 15, 2021
Assignees:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN, OHIO STATE INNOVATION FOUNDATION
Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85% w/w API particles; 15-30% w/w coating material coating the API particles; and 3-15% w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60% relative humidity.
Type:
Grant
Filed:
August 31, 2020
Date of Patent:
June 8, 2021
Assignee:
Catalent U.K. Swindon Zydis Limited
Inventors:
Rosaleen McLaughlin, Simon Andrew Martyn Howes, Craig Wheadon, Jonathon Whitehouse
Abstract: The present invention proposes a new way of having makeup last longer on the skin. The present invention comprises the supply and use of a new liquid cosmetic composition comprising the combining of styrene/acrylates copolymer and Biosaccharide Gum-4 preferably in an aqueous solution. This makeup-fixing composition is intended to be sprayed on top of makeup compositions, after they have been applied to the skin, so as to delay the deterioration of makeup compositions and thus having the makeup last longer.
Abstract: The present invention provides a cosmetic product capable of making the skin look youthful and producing a natural three-dimensional appearance. The present invention relates to a cosmetic product including two or more phosphors each containing an inorganic compound, wherein the cosmetic product, upon excitation by excitation light having a wavelength of 365 nm, emits an emission spectrum having a fluorescence emission peak in each of the range of 400 to 530 nm and the range of 620 to 720 nm and having an I2/I1 of 1 to 30, where I1 is a maximum emission intensity in the range of 530 to 620 nm and I2 is a maximum peak intensity in the range of 620 to 720 nm.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
June 1, 2021
Assignee:
Sakai Chemical Industry Co., Ltd.
Inventors:
Hisao Koizumi, Momoko Ishikawa, Nanae Ogata, Kenji Mori
Abstract: The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.
Abstract: The present invention provides for a method for the treatment of a viral disease, disorder or condition in a subject, the method comprising the step of administering to said subject a medically active liquid in nebulized form by inhalation, wherein the medically active liquid comprises remdesivir or a pharmaceutically acceptable salt thereof and wherein the medically active liquid is administered in nebulized form using an inhalation device.
Abstract: Provided herein are compositions, systems, kits, and methods for treating cancer in at least one bone of a subject using nanoparticles encapsulating, or conjugated to, an anti-cancer agent. In other embodiments, provided herein are composition, systems, kits, and methods for treating a bone disease (e.g., osteoporosis) in a subject using nanoparticle encapsulating, or conjugated to, a RANKL inhibitor. The nanoparticle are, in certain embodiments, neutral or nearly neutral in charge (e.g., zeta potential between ?5 and +5 mV) and less than 250 nm in diameter on average (e.g. have an average diameter between 100 and 200 nm).
Abstract: Liquid nutritional compositions include functional ingredients such as beta-hydroxy-beta-methylbutyrate, docosahexaenoic acid, and lutein. The nutritional compositions are useful to promote at least one of physical performance (e.g., body composition, muscle mass, muscle strength) and cognitive function (e.g., focus, attention, alertness, executive function) in an individual. The functional ingredients are incorporated into the nutritional composition in such a way that they do not adversely affect the desirable properties of the nutritional composition such as, for example, nutritional value, stability, solubility, taste, and mouthfeel.
Abstract: The present disclosure relates to pharmaceutical compositions comprising N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide and a polymer, dosage forms comprising the formulation and methods of treating subjects having cancer.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
May 18, 2021
Assignee:
IGNYTA, INC.
Inventors:
Robert Orr, Kathryn Emily Colombo Pugh, Matthew Jarud Shaffer, Brent Antone Uhrig, Edward Dennis Lachapelle, Charlie Michael McLaughlin
Abstract: A liquid composition which comprises an organic liquid diluent and at least one non-ionic cellulose ether having a viscosity of up to 2.33 mPa·s, measured as a 2 wt.-% solution in water at 20° C., is stable over an extended time period. The liquid composition is useful for preparing a solid dispersion comprising at least one active ingredient in at least one cellulose ether by spray-drying. Alternatively a solid dispersion can be produced by blending and extruding at least one active ingredient, at least one cellulose ether having a viscosity of up to 2.33 mPa·s and optionally one or more adjuvants.
Type:
Grant
Filed:
March 19, 2019
Date of Patent:
May 11, 2021
Assignee:
Dow Global Technologies LLC
Inventors:
Meinolf Brackhagen, Nicholas S. Grasman, Mark J. Hall, Steven J. Guillaudeu, Robert L. Schmitt, Matthias Knarr
Abstract: Disclosed is a scaffold for living donor transplantation, which includes sintered bioglass and a biocompatible polymer and has improved properties using a 3D printer through a fused deposition modeling process.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
May 4, 2021
Assignees:
CG BIO CO., LTD., BIOALPHA INC.
Inventors:
Jun Young Lim, Yong Bok Kim, Hyun Seung Ryu
Abstract: The invention relates to compositions and uses thereof in methods for treating an inflammatory disease, disorder or condition in a subject, in particular an inflammatory disease, disorder or condition of the digestive tract such as inflammatory bowel disease (IBD) and/or colorectal cancer. The invention also relates to probiotic compositions and the use of the compositions for treating gastrointestinal disorders.
Type:
Grant
Filed:
September 21, 2017
Date of Patent:
April 27, 2021
Assignee:
CHAIN Biotechnology Limited
Inventors:
Benjamin Bradley, Edward Green, Daniela Heeg
Abstract: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Abstract: Hollow fiber drug delivery devices are described. Device can contain structural or solid fibers. Fabric can be formed by fibers being interwoven or joined to each other. All or some of the fibers can be resorbable. Fibers can be subdivided, by deformations or closure points, into numerous compartments that separately deliver drug. Deformations can be located at points of fiber intersection or joining. Different drug or drug formulation can be provided in different places. Fibers can be given appropriate surface treatments or coatings to achieve desired properties such as wetting of pores and surfaces. Different release characteristics in different directions can be achieved. The hollow fibers can contain solid particles of drug, and can contain gel. Possible applications include hernia meshes, pouches, sutures, catheters, wound dressings, stents, nerve regrowth guides, refillable/drainable devices, and devices that deliver drug to lymphatic flow.
Type:
Grant
Filed:
December 12, 2019
Date of Patent:
March 23, 2021
Assignee:
Novaflux, Inc.
Inventors:
Mohamed E. Labib, Stanislav S. Dukhin, Peter Materna, Jeffrey C. Robertson, Ching-Yue Lai, Yacoob Tabani